Concentrated Radionuclide Complex Solutions with Dual Stabilizers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing radiopharmaceutical drug products face issues with radiolytic degradation during manufacturing and storage, leading to instability and the need for on-site preparation, which complicates administration and patient comfort due to high dilution requirements and potential physiological issues from ethanol use.
Innovation Solution
A pharmaceutical aqueous solution containing a radionuclide complex stabilized by a combination of gentisic acid and ascorbic acid, allowing high concentration and stability at ambient temperatures, enabling commercial production and ready-to-use infusion solutions without ethanol.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If radiopharmaceutical drug products are produced in high concentration, then the volume of infusion solution administered to patients is reduced, but the solutions are more prone to radiolysis and degradation
Solution Approach 1:
The patent introduces stabilizers (ascorbic acid, gentisic acid, or ethanol) as intermediary substances that protect the radionuclide complex from radiolysis. These stabilizers act as mediators between the high-concentration radionuclide solution and the harmful radiolytic degradation, enabling high concentration while maintaining stability through their radical-scavenging properties.
Solution Approach 2:
The patent changes the chemical composition parameters of the solution by adding specific stabilizers (ascorbic acid at 0.1-10 mM, gentisic acid at 0.1-10 mM, or ethanol at 1-50% v/v) to alter the radiolytic stability parameter, allowing the solution to maintain high radiochemical stability even at high radionuclide concentrations.
2Stability of the object's composition
If stabilizers are added to prevent radiolysis, then radiochemical stability is improved, but the stabilizers may have negative impact on complexation or solubility
Solution Approach 1:
The patent optimizes the concentration parameters of stabilizers (ascorbic acid 0.1-10 mM, gentisic acid 0.1-10 mM, ethanol 1-50% v/v) to achieve the desired radiochemical stability while maintaining adequate complexation efficiency and solubility, balancing multiple competing requirements through parameter optimization.
3Stability of the object's composition
If radiopharmaceuticals are manufactured as individual patient doses in hospital laboratories, then radiochemical stability is maintained, but patient comfort and administrative complexity are worsened due to on-site preparation requirements
Solution Approach 1:
The patent applies preliminary action by pre-stabilizing the radionuclide complex solution with stabilizers before administration, allowing the solution to be prepared in advance at high concentration and stored with maintained stability, eliminating the need for on-site reconstitution and preparation while preserving radiochemical integrity.
Solution Approach 2:
The patent enables continuity of useful action by allowing the radiopharmaceutical to be prepared, stored, and administered without interruption or reconstitution steps. The stabilizers maintain radiochemical stability throughout storage and handling, enabling seamless continuous operation from manufacturing to patient administration.
4Stability of the object's composition
If ethanol is used as stabilizer, then radiochemical stability is improved, but physiological tolerability and patient comfort are reduced
Solution Approach 1:
The patent changes the chemical composition by offering alternative stabilizers (ascorbic acid, gentisic acid) with different physiological properties to replace or reduce ethanol content, optimizing the balance between radiochemical stability and patient tolerability through compositional parameter modification.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides high chemical and radiochemical stability, allowing for centralized production and shipment of ready-to-use radiopharmaceuticals with a shelf-life of at least 3 days, reducing patient discomfort and administrative complexity.
Implementation Method 1
the decay of the radionuclide occurs constantly, e.g. also during the manufacturing and during storage of the drug product, and the released high energy emissions induce the cleavage of the chemical bonds of the molecules which form part of the drug product. This is often referred to as radiolysis or radiolytic degradation.
Implementation Method 2
A pharmaceutical aqueous solution containing a radionuclide complex stabilized by a combination of gentisic acid and ascorbic acid, allowing high concentration and stability at ambient temperatures
Data Source
AI summary
The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.